Effects of COVID-19 Infection and Critical Illness on Diaphragm Tissue Characteristics and Movement, Visualized With MRI

Effects of COVID-19-infection and Mechanical Ventilation on Movement and Tissue Characteristics of the Diaphragm, Visualized by Magnetic Resonance Imaging: a Proof-of-concept Study

COVID-19-infection has a large impact on the respiratory system and possibly on the diaphragm, the main respiratory muscle. In ICU-patients, diaphragm weakness is associated with prolonged ICU-stay, difficult weaning and increased mortality. Our research group recently found evidence for fibrosis and expression of genes involved in fibrosis as well as viral infiltration of the SARS-CoV-2 virus in diaphragm biopsies from COVID-19 ICU patients. This finding suggests a unique manifestation of diaphragm injury in COVID-19 patients after mechanical ventilation. However, it remains unclear what the exact nature and location of diaphragm injury is.

Additionally, it is largely unknown whether this injury affects the movement of the diaphragm, but this might have important clinical implications. Therefore, we aim at visualizing the tissue characteristics and movement of the diaphragm in COVID-19 patients who recently received long-term mechanical ventilation, other ICU patients and healthy controls, using magnetic resonance imaging (MRI). MRI of the diaphragm was already shown feasible in previous research from our group (article currently under review).

New insights in the characteristics of diaphragm weakness and injury in COVID-19 patients and control ICU-patients will contribute to strategies to prevent it and monitor the diaphragm of patients under mechanical ventilation, which can contribute to better patient outcomes.

Inclusion criteria

In order to be eligible to participate in this study, a subject in the case group must meet all of the following criteria:

• Invasive mechanical ventilation > 72 hours during current hospital admission
• Admitted for COVID-19-infection (n = 10)
• Currently negative COVID-19 PCR test
• Discharged from the ICU ≤ 7 days ago
• Signed informed consent
• Age ≥ 18 years

In order to be eligible to participate in this study, a subject in the control group must meet all of the following criteria:

• Signed informed consent
• Age ≥ 18 years
• Similar age (max 5 years difference) and gender of one of the subjects in case group

Exclusion criteria

A potential subject for the case group who meets any of the following criteria will be excluded from participation in this study:

• Known history of:

  • Diaphragmatic injury or weakness prior to ICU stay
  • COPD (GOLD IV)
  • Neuromuscular disease (including pathology of the n. phrenicus)
  • Connective tissue disease
  • Chronic use of corticosteroids (>7.5 mg/day for at least 3 months before hospital admission)
  • >10% weight loss within last 6 months prior to ICU admission

• Obesity (BMI > 30 kg/m2 at hospital admission)

• Known pregnancy

• Contraindications for MRI

  • Electrical/metallic implants
  • Claustrophobia

• Unable to hold breath for 10 seconds

• Hierarchical relation with one of the collaborating investigators

• Incapacitation

• Contraindications for the use of a Gadolinium based contrast agent for MRI

  • Known eGFR < 30 ml/min/1.73m2
  • Known history of allergic reactions to an MRI contrast medium
  • Known history of allergic reactions requiring immediate treatment
  • Known history of atopy
  • Asthma These exclusion criteria are based on the guidelines for contrast agents from the European Society for Urogenital Radiology (http://www.esur.org/guidelines/).

Additional exclusion criteria for the case group, subset non-infected patients are:

• History of COVID-19-infection (confirmed with positive test)

Additional exclusion criteria for the control group are:

• History of mechanical ventilation > 24 hours
• History of COVID-19-infection (confirmed with positive test)